Abstract:Melanoma, a lethal malignancy that arises from melanocytes, exhibits a multiplicity of clinico-pathologically distinct subtypes in sun-exposed and non-sun-exposed areas. Melanocytes are derived from multipotent neural crest cells and are present in diverse anatomical locations, including skin, eyes, and various mucosal membranes. Tissue-resident melanocyte stem cells and melanocyte precursors contribute to melanocyte renewal. Elegant studies using mouse genetic models have shown that melanoma can arise from either melanocyte stem cells or differentiated pigment-producing melanocytes depending on a combination of tissue and anatomical site of origin and activation of oncogenic mutations (or overexpression) and/or the repression in expression or inactivating mutations in tumor suppressors. This variation raises the possibility that different subtypes of human melanomas (even subsets within each subtype) may also be a manifestation of malignancies of distinct cells of origin. Melanoma is known to exhibit phenotypic plasticity and trans-differentiation (defined as a tendency to differentiate into cell lineages other than the original lineage from which the tumor arose) along vascular and neural lineages. Additionally, stem cell-like properties such as pseudo-epithelial-to-mesenchymal (EMT-like) transition and expression of stem cell-related genes have also been associated with the development of melanoma drug resistance. Recent studies that employed reprogramming melanoma cells to induced pluripotent stem cells have uncovered potential relationships between melanoma plasticity, trans-differentiation, and drug resistance and implications for cell or origin of human cutaneous melanoma. This review provides a comprehensive summary of the current state of knowledge on melanoma cell of origin and the relationship between tumor cell plasticity and drug resistance.

Multiple Tumor Types May Originate from Bone Marrow-Derived Cells

Accumulated Chromosomal Instability in Murine Bone Marrow Mesenchymal Stem Cells Leads to Malignant Transformation

Chemically-induced Cancers Do Not Originate from Bone Marrow-Derived Cells.

Tumor can originate from not only rare cancer stem cells

Generation of pluripotent cancer-initiating cells from transformed bone marrow-derived cells.

Hemangioblastomas Might Derive from Neoplastic Transformation of Neural Stem Cells/Progenitors in the Specific Niche

Multiple cells of origin in common with various types of mouse N-Myc acute leukemia

The role of bone marrow-derived cells in the origin of liver cancer revealed by single-cell sequencing

Activation of the Germ-Cell Potential of Human Bone Marrow-Derived Cells by a Chemical Carcinogen

Several types of soft tissue sarcomas originate from the malignant transformation of adipose tissue-derived stem cells

Stem Cell Theory of Cancer: Origin of Tumor Heterogeneity and Plasticity

Connecting the dots: Melanoma cell of origin, tumor cell plasticity, trans-differentiation, and drug resistance

The Commonality of Plasticity Underlying Multipotent Tumor Cells and Embryonic Stem Cells

Bone Marrow Mesenchymal Stem Cell Has Poor Proliferation but Non-Tumorigenicity in Cancer Environment

Somatic-to-primordial germ cell-like transformation is critical in tumor initiation of mouse breast tumor 4T1 cells.

Stem cells in mammary development and carcinogenesis

The Role of Stem Cells in Benign Tumors

Single cell profiling of bone metastasis ecosystems from multiple cancer types reveals convergent and divergent mechanisms of bone colonization.

A unique malignant cell type per patient tumor is encoded in each cancer cell transcriptome.

Seeing is Believing: Are Cancer Stem Cells the Loch Ness Monster of Tumor Biology?

A self-renewal program controls the expansion of genetically unstable cancer stem cells in pluripotent stem cell-derived tumors.